

Traitements chirurgicaux du diabète



Université Lille Nord de France





Francois Pattou

Chirurgie Générale et Endocrinienne, CHRU de Lille

INSERM UMR 859 - Biotherapies for Diabetes

LABEX - European genomic institute for diabetes

Thérapie cellulaire / diabète de type 1



Pattou et al. *New England J Med* 2010

Vantyghem et al. *J Clin Endocrinol Metab* 2012

Diabète de type 2



> 4 % de la population française

17 milliards d'euros de dépenses de santé en 2011



diabetes care

GREAT BUY!





Chirurgie métabolique ?

Efficace

Explicable


Durable

Sur






Chirurgie bariatrique

Gastric banding



Sleeve gastrectomy




Gastric bypass

Duodenal switch


> 35 000
interventions / an
en France

Perte de poids




Sjostrom et al. *New Engl J Med* 2004 ; 2007 - *JAMA* 2012

Surgery or Medical Therapy for Obese Patients with Type 2 Diabetes?



Value at Visit



Intensive medical therapy	8.9	7.7	7.1	7.4	7.5
Roux-en-Y gastric bypass	9.3	6.8	6.3	6.4	6.4
Sleeve gastrectomy	9.5	7.1	6.7	6.7	6.6



Schauer et al , Mingrone et al. New Engl J Med 2012 On line (26/03)

Contrôle du diabète

Best medical care alone (60) vs gastric bypass (60)





Composite end point
 $\text{HbA1c} < 7.0\%$
 $\text{LDL cholesterol} < 100 \text{ mg/dL}$
 $\text{PA systolique} < 130 \text{ mm Hg}$

Ikramuddin et al et al. JAMA 2012

19% vs 49%
Odds ratio 4.8 (95% CI, 1.9-11.7)

Chirurgie et mortalité / obèses




Sjostrom JAMA 2012



Effet transgénérationnel

Enfants nés de mères obèses **avant** vs **après** chirurgie




Smith et al. J Clin Endocrinol Metab 2009



Guenard et al. PNAS 2013



1. Explicable ?




Life long caloric restriction





Colman et al *Science* 2009

Diabetes incidence




Ashcroft Cell 2012

Restriction anatomique




Les interventions ne sont pas égales

217 patients
with diabetes




Brethauer Ann Surg 2013

Effet indépendant de la perte de poids ?






Obediab study



Excursion glycémique postprandiale



Longitudinal mixed meal test study in **diabetic** individuals (OBEDIAB)




Healthy controls (n=10) / **Gastric bypass (n=26)** / Band (n=20)

(unpublished data)

Changement hormonaux




Longitudinal mixed meal test study in **diabetic** individuals (OBEDIAB)




(unpublished data)

Instestin et diabète ?

Microbiote ?




Glucose intestinal uptake ?




Liou *Science Translat Med* 2013

Saeidi *Science* 2013






2. Prédicteur ?



Diabetes Remission




Arterburn et al. *Obesity Surg* 2013

Prédire la rémission du diabète


154 T2DM patients submitted to GBP

1. Diabetes duration < 4 years
2. BMI > 35 kg/m²
3. C-peptide < 2.9 ng/mL



Dixon et al. *Diabetes Care* 2013

System biology / Obesity surgery




Walter et al. *Nature* 2010
Ichimura et al. *Nature* 2012

ABOS Longitudinal study / 1000 patients




3. Durable ?



Résultats / 5 ans




Longitudinal study in 26 individuals with DT2M after GBP



(unpublished data)


Récidive du diabète / BMI



Arterburn et al. *Obesity Surg* 2013



4. Sure ?



Risque Péri-opératoire

Table 2. Adverse Outcomes within 30 Days after Surgery, According to Surgical Procedure.

Outcome	Total (N=4610)*	Laparoscopic Adjustable Gastric Banding (N=1198)	Laparoscopic Roux-en-Y Gastric Bypass (N=2975)	Open Roux-en-Y Gastric Bypass (N=437)	P Value†
number (percent)					
Death	15 (0.3)	0	6 (0.2)	9 (2.1)	<0.001
Deep-vein thrombosis or venous thromboembolism	20 (0.4)	3 (0.3)	12 (0.4)	5 (1.1)	0.05
Tracheal reintubation	20 (0.4)	2 (0.2)	12 (0.4)	6 (1.4)	0.004
Endoscopy	51 (1.1)	1 (0.1)	45 (1.5)	5 (1.1)	<0.001
Operation					
Tracheostomy	11 (0.2)	0	6 (0.2)	5 (1.1)	0.001
Placement of percutaneous drain	16 (0.3)	0	13 (0.4)	3 (0.7)	0.48
Abdominal operation	118 (2.6)	9 (0.8)	94 (3.2)	15 (3.4)	<0.001
Failure to be discharged by day 30	17 (0.4)	0	13 (0.4)	4 (0.9)	0.02
Composite end point‡	189 (4.1)	12 (1.0)	143 (4.8)	34 (7.8)	<0.0001

Long term benefits and risks ?




Reprise de poids / récidive du diabète
Effets secondaires inattendus
Effets transgénérationnels ?

Bénéfice clinique ?




Mortality



Adapted from UKPDS *New Engl J Med* 2008

Duodeno jejunal bypass (Endobarrier)



Tarnoff *Surg Endosc* 2009
Schouten *Ann Surg* 2010
Gersin *Gastrointest Endosc* 2010
De Moura *Ob Surg* 2011
Escalona *Ann Surg* 2012

En résumé




Thank you ...

Endocrine Surgery

Robert Caiazzo
Fanelly Torres
Violeta Raverdy
Adrien Sterkers
Carole Eberle
Sarah Surmont
Marie Clément

Nutrition

Monique Romon
Marie Pigeyre
Helene Werkindt



EGID
Philippe Froguel
Bart Staels

INSERM U 859
Biotherapies for diabetes

Julie Kerr-conté
Valery Gmyr
Philippe Lefebvre
Brigitte Vandewalle
Thomas Hubert



Diabetology
Marie Christine Vantyghem
Pierre Fontaine
Catherine Fermont